BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 34730838)

  • 1. Circ_0000376 downregulation inhibits the progression of non-small cell lung cancer by mediating the miR-488-3p/BRD4 axis and the PI3K/PKB signaling pathway.
    Yuan H; Wu H; Cheng J; Xiong J
    Histol Histopathol; 2021 Dec; 36(12):1309-1324. PubMed ID: 34730838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circular RNA circ_0074027 indicates a poor prognosis for NSCLC patients and modulates cell proliferation, apoptosis, and invasion via miR-185-3p mediated BRD4/MADD activation.
    Gao P; Wang Z; Hu Z; Jiao X; Yao Y
    J Cell Biochem; 2020 Mar; 121(3):2632-2642. PubMed ID: 31680319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0074027 contributes to non-small cell lung cancer progression through positively modulating RHOA via sequestering miR-2467-3p.
    Duan Z; Wei S; Liu Y
    J Bioenerg Biomembr; 2021 Apr; 53(2):223-233. PubMed ID: 33687619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA hsa_circ_0072309 inhibits non-small cell lung cancer progression by sponging miR-580-3p.
    Pang W; Huang F; Zhang X; Ye M; Huang Y; Huang X; Pang J; Cai C; Wang Z
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32293004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway.
    Zhao M; Ma W; Ma C
    Biomed Pharmacother; 2020 Sep; 129():110461. PubMed ID: 32768951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNA circ_0006089 promotes the progression of gastric cancer by regulating the miR-143-3p/PTBP3 axis and PI3K/AKT signaling pathway.
    Lin GR; Chen WR; Zheng PH; Chen WS; Cai GY
    J Dig Dis; 2022 Jul; 23(7):376-387. PubMed ID: 35844201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of circ-RAD23B inhibits non-small cell lung cancer progression via the miR-142-3p/MAP4K3 axis.
    Zhuang Q; Huang Z; Zhuang W; Hong Y; Huang Y
    Thorac Cancer; 2022 Mar; 13(5):750-760. PubMed ID: 35106926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of circ-SFMBT2 blocks the development of gastric cancer by targeting the miR-885-3p/CHD7 pathway.
    He Y; Zhang Z; Wang Z; Jiao Y; Kang Q; Li J
    Anticancer Drugs; 2022 Jan; 33(1):e247-e259. PubMed ID: 34387601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bufalin inhibits the malignant development of non-small cell lung cancer by mediating the circ_0046264/miR-522-3p axis.
    Jin J; Yao Z; Qin H; Wang K; Xin X
    Biotechnol Lett; 2021 Jun; 43(6):1229-1240. PubMed ID: 33534015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circ-PGC increases the expression of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer.
    Xia D; Chen Z; Liu Q
    Cell Cycle; 2021 Nov; 20(21):2195-2209. PubMed ID: 34494941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of hsa_circ_0007580 inhibits non-small cell lung cancer tumorigenesis by reducing miR-545-3p sponging.
    Chen S; Lu S; Yao Y; Chen J; Yang G; Tu L; Zhang Z; Zhang J; Chen L
    Aging (Albany NY); 2020 Jul; 12(14):14329-14340. PubMed ID: 32681720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC).
    Tang YF; Liu ZH; Zhang LY; Shi SH; Xu S; Ma JA; Hu CH; Zou FW
    Mol Cancer; 2024 May; 23(1):91. PubMed ID: 38715012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA hsa_circ_0000317 inhibits non-small cell lung cancer progression through regulating microRNA-494-3p/phosphatase and tensin homolog deleted on chromosome 10 axis.
    Xia S; Zhang Z
    Clinics (Sao Paulo); 2022; 77():100086. PubMed ID: 35917658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circ_0074027 contributes to the progression of non-small cell lung cancer via microRNA-362-3p/clathrin heavy chain axis.
    Jiang Z; Yin J; Peng G; Long X
    Anticancer Drugs; 2021 Jan; 32(1):1-10. PubMed ID: 32932275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0011292 knockdown mitigates progression and drug resistance in PTX-resistant non-small-cell lung cancer cells by regulating miR-433-3p/CHEK1 axis.
    Jin M; Zhang F; Li Q; Xu R; Liu Y; Zhang Y
    Thorac Cancer; 2022 May; 13(9):1276-1288. PubMed ID: 35348291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ-ZNF124 downregulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/β-catenin signaling pathway via mediating the miR-498/YES1 axis.
    Gao F; Jia L; Han J; Wang Y; Luo W; Zeng Y
    Anticancer Drugs; 2021 Mar; 32(3):257-268. PubMed ID: 33186139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA circ_0010235 sponges miR-338-3p to play oncogenic role in proliferation, migration and invasion of non-small-cell lung cancer cells through modulating KIF2A.
    Zhu Y; Ma C; Lv A; Kou C
    Ann Med; 2021 Dec; 53(1):693-706. PubMed ID: 34024242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsa_circ_0006677 regulates special AT-rich binding protein-2-mediated tumor-suppressive effect via functioning as a miR-1245a sponge in non-small cell lung cancer.
    Sui X; Liu Z; Niu L; Yin B; Huo C
    Bioengineered; 2022 Feb; 13(2):3760-3774. PubMed ID: 35081869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.